Incorporation of the company and start of development of the two technology platforms Sagitta and NanoHybrid. The first patent on biosensors for antibodies was registered.
Ulisse BioMed raised €1mn in a seed round led by Copernico Innovazione S.r.l. and was awarded grants for a total of €1.5mn. This allowed the company to open its laboratory in Trieste and file the first patent about NanoHybrid.
The company completed the first test prototype and raised €4mn among 1.154 retail shareholders by issuing preferred shares. The company filed three patents related to Sagitta and NanoHybrid.
The company obtained the ISO13485 IVD certification – required to produce CE-IVD marked medical devices – and started a collaboration with the Institute for Human Virology. UBM filed two patents having as underlying technologies biomarkers and aptamers.
Ulisse BioMed obtained clinical validation of LadyMed, performed area tests to identify the most suitable distribution channel and found a lab partner and first private hospital customer (Campus BioMedico).
The company signed a technology transfer agreement with Menarini Diagnostics S.r.l., for production, distribution and commercialisation of Coronamelt and Coronamelt Var, two core products of UBM based on Real Time PCR aimed at the detection of Covid-19 and its variants.
Menarini Diagnostics Srl has started the production of Coronamelt and has announced the launch of Coronamelt Var by September 2021.